Context: Low plasma high-density lipoprotein (HDL) cholesterol is a major abnormality in abdominal obesity. This relates due to accelerated HDL catabolism, but the underlying mechanism requires further elucidation. The relationships between HDL catabolism and other variables that may be modified in abdominal obesity, such as very low-density lipoprotein (VLDL) subspecies (VLDL 1 , VLDL 2 ) kinetics, liver fat, or visceral adiposity, remain to be investigated.
dividuals have shown that low plasma concentration of HDL cholesterol is the consequence of increased HDL catabolism (7) (8) (9) . However, among abdominally obese subjects, there is a large variability in apolipoprotein (apo)-A-I fractional catabolic rate (FCR) that requires investigation.
We have previously shown that HDL-apoA-I catabolism is positively correlated with very low-density lipoprotein (VLDL)-apoB production rate (8) . However, some questions remained unanswered. Indeed, the link between apoA-I FCR and VLDL subspecies, whose evaluation is critical to the metabolic syndrome or type 2 diabetes, has not been studied. Lipoprotein kinetic studies have shown that VLDL are metabolically heterogeneous, with accumulating evidence demonstrating that both the production and catabolism of large triglyceride-rich VLDL 1 (Sf 60 -400) and smaller cholesterol-rich VLDL 2 are regulated independently of each other (10) . The separate evaluation of VLDL 1 and VLDL 2 metabolism is important in the metabolic syndrome or type 2 diabetes, conditions in which the hepatic oversecretion of VLDLs is mainly due to increased secretion of the triglyceride-rich VLDL 1 particles (11, 12) . Thus, it is important to analyze precisely the kinetic associations between HDL-apoA-I and both VLDL 1 and VLDL 2 lipoproteins. VLDL 1 secretion has been shown to be positively correlated with liver fat and visceral fat (11) . However, liver fat and visceral fat were not determined in previous kinetics studies of HDL-apoA-I, and it is not clear whether the association between HDL-apoA-I catabolism and the VLDL (or VLDL 1 ) secretion rate is a direct one or is indirectly mediated by the extent of ectopic fat in the liver and visceral/sc regions of the abdomen.
To extend our previous findings on the association between apoA-I and VLDL kinetics, we investigated in a relatively large multicenter tracer study the relationships of apoA-I catabolism with the kinetics of VLDL subspecies and hepatic, visceral, and sc fat compartments in abdominally obese individuals.
Research Design and Methods

Study cohort
Sixty-two subjects were recruited at three study centers according to the following inclusion criteria: men or postmenopausal women, 35-65 years of age, BMI greater than 25 kg/m 2 and less than 40 kg/m 2 , abdominal obesity according to National Cholesterol Education Program/Adult Treatment Panel III (waist circumference Ͼ88 cm for women and Ͼ102 cm for men), and at least one lipid abnormality (plasma triglycerides Ͼ1.7 mmol/L and Ͻ4.5 mmol/L and/or HDL cholesterol Ͻ1.29 mmol/L for women and Ͻ1.03 mmol/L for men).
Exclusion criteria were HDL cholesterol below 0.6 mmol/L, total cholesterol above 6.5 mmol/L or genetic hyperlipidemia, apoE2/E2 or apoE4/E4 homozygosity, type 2 diabetes treated with oral agents and/or insulin, a history of cardiovascular disease, systolic blood pressure above 160 mm Hg or diastolic blood pressure above 95 mm Hg, a history of surgical procedures for weight loss, the presence of any clinically significant endocrine disease, severe hepatic impairment (aspartate aminotransferase or alanine aminotransferase greater than 3 times the upper limit of normal) or renal function (creatinine clearance Ͻ30 mL/min), or proteinuria (Ͼ30 mg/dL). Subjects were not allowed any lipidlowering drugs, antiobesity drugs, nonselective ␤-blockers, or agents known to affect lipid metabolism. Individuals with histories of alcohol and/or drug abuse, current smoking, or smoking cessation within the past 3 months were also excluded.
Subjects were advised to follow a weight-maintenance diet for 6 weeks before the kinetic studies. Body weight was measured with participants wearing undergarments or very light clothing and no shoes. Subjects with greater than 3% variation in weight during this period were excluded from the study. Waist circumference was recorded at the midpoint between the lower rib margin and the iliac crest. Three consecutive readings were taken and the mean was recorded.
Study design
The protocol included three study visits comprising a fasting kinetic study, determination of intraabdominal fat depots, and a heparin test on separate dates. The ethics committee at each site approved the study design and each subject gave written informed consent before participation in the study (trial registered as number NCT00408148).
Kinetic protocol, isolation of lipoproteins, and biochemical analyses
The subjects were admitted at 7:30 AM and baseline blood samples for the kinetic study and biomarkers (apoA-I, apoA-II, apoB, apoCIII, apoE, lipoprotein A (LpA)-I, glucose, insulin, and LDL particle size) were taken. At 8:00 AM, a bolus injection of [1, 1, 2, 3, H 5 ]glycerol (500 mg) and [5, 5, H 3 ]leucine (7 mg/kg) was given and blood drawn as previously described (13) . Isolation of VLDL 1 and VLDL 2 and measurements of isotopic enrichment of leucine in apoB and glycerol in triglycerides were performed as previously described (13) . Total apoB and triglyceride content in VLDL 1 and VLDL 2 were determined at 0, 4, and 8 hours after tracer injection. Biochemical analyses were performed and LDL peak size was measured as previously described (14) .
Isolation of apolipoproteins and glycerol: measurement of isotopic enrichment VLDL 1 and VLDL 2 were isolated from plasma as previously reported (13) . HDL-apoA-I and HDL-apoA-II were isolated from plasma by sequential ultracentrifugation, separated by SDS-PAGE, and blotted on to a polyvinylidene fluoride membrane. ApoB (isolated from VLDL 1 and VLDL 2 ) and ApoA-I and apoA-II (isolated from HDL) were hydrolyzed, derivatized, and subjected to gas chromatography mass spectrometer to measure tracer leucine enrichment, as previously reported (13, 15) .
Triglycerides were isolated from VLDL 1 and VLDL 2 fractions and the tracer glycerol enrichment determined as previously reported (13) .
Modeling
Apoprotein enrichment data were modeled using SAAM-II (The Epsilon Group) (16 2 , and the enrichment curves of plasma leucine and glycerol in VLDL 1 and VLDL 2 leucine and glycerol were used for a multicompartment model that allowed simultaneous modeling of apoB and triglycerides kinetics as previously described (13) and shown in Figure 1 . ApoA-I modeling was performed using a multicompartment model as previously detailed (17) . Briefly, the apoA-I model includes a four-compartment subsystem (compartments 1-4) that describes plasma leucine kinetics. This subsystem is connected to an intrahepatic delay compartment, compartment 5, that accounts for the time required for the synthesis and secretion of apoA-I into plasma. Compartment 6 describes the kinetics of apoA-I in the plasma HDL fraction. ApoA-II modeling was performed using the apoA-I model. The FCR was equivalent to the loss from compartment 6, and the PR (mg/ kg Ϫ1 ⅐ d Ϫ1 ) was calculated as the product of FCR and apoA-I (or apoA-II) pool sizes.
Determination of liver and sc and visceral fat
Liver fat was determined using proton magnetic resonance spectroscopy, and sc abdominal and visceral fat were measured by magnetic resonance imaging as previously described (11) . (19) . Plasma CETP and PLTP activity levels were related to the activity in a reference plasma analyzed in each run and are expressed in arbitrary units (AU).
Analytical procedures
Statistical analysis
Data are reported as mean Ϯ SD. Statistical calculations were performed using the SPSS software package (SPSS Inc). For continuous variables, a Kolmogorov-Smirnov analysis was performed to test for normality. The Pearson correlation coefficients (r) were determined by linear regression analysis. Statistical significance of the correlation coefficients was determined by the method of Fisher and Yates. Multivariable analyses were performed by stepwise linear regression, including into the model all the variables that correlated in univariate analysis with P Յ .10 and potential confounding factors such as age, gender, and study center. For multivariable analyses, data that were not normally distributed were log transformed. A two-tailed probability level of P ϭ .05 was accepted as statistically significant.
Results
Main characteristics of the abdominally obese population
The clinical and biochemical characteristics of the population are shown in Table 1 . The subjects were abdominally obese, with a mean BMI of 32.3 Ϯ 3.33 kg/m 2 , large waist circumference (108 Ϯ 8 cm), and high insulin resistance [mean homeostasis model assessment index of insulin resistance (HOMA-IR) value of 3.14 Ϯ 1.88]. In addition, the subjects also exhibited the typical dyslipidemia of the metabolic syndrome with high plasma triglycerides and low HDL cholesterol (HDL-C) concentrations. Table 2 presents the kinetic data for apoA-I, apoA-II, VLDL 1 -triglycerides (TGs), VLDL 2 -TGs, VLDL 1 -apoB, and VLDL 2 -apoB of the abdominally obese population.
Correlations between main lipid, morphological, and kinetic parameters
The correlation coefficients between the main lipid, morphological, and kinetic parameters are shown in Table  3 . apoA-I FCR was positively correlated with BMI, sc fat, liver fat, HOMA-IR, plasma TGs, VLDL 1 -TGs and VLDL 1 -apoB concentrations and negatively with HDL-C, HDL-C to apoA-I ratio, and HDL-C to apoA-II ratio. As far as kinetic parameters are concerned, apoA-I FCR was positively correlated with apoA-I production rate (PR), apoA-II FCR, apoA-II PR, VLDL 1 -triglycerides PR, and VLDL 1 -apoB PR. A borderline negative correlation was observed between apoA-I FCR and VLDL 1 -TG indirect FCR (r ϭ Ϫ0.247, P ϭ .054).
Independent predictors for apoA-I catabolism
Because there was a strong correlation between apoA-I FCR and apoA-I PR (r ϭ 0.900, P Ͻ .0001), we focused on independent factors regulating apoA-I FCR by multivariable analyses.
First, we analyzed the morphological and biological parameters that may predict apoA-I FCR. With this multivariable statistical model, liver fat and plasma TGs were found to be independent predictor variables for apoA-I FCR (Table 4 , predictor variables, model 1). When plasma TGs were replaced into the model, by VLDL 1 -TG concentration, both liver fat and VLDL 1 -TG concentration were found to be independent predictor variables for apoA-I FCR (Table 4 , predictor variables, model 2). When plasma TGs were replaced into the model, by VLDL 1 -apoB concentration, both liver fat and VLDL 1 -apoB concentration were found to be independent predictor variables for apoA-I FCR (Table 4 , predictor variables, model 3). The introduction of both VLDL 1 -TG and VLDL 1 -apoB into the model gave identical results with those obtained with model 3.
Next, we analyzed the morphological and biological parameters that may be consequent variables of apoA-I FCR. With this multivariable statistical model, the HDL-C to apoA-I ratio and age were independently associated with apoA-I FCR (Table 4 , consequential variables).
We finally analyzed the kinetic parameters that may be independently associated with apoA-I FCR. For this purpose, we performed a multivariable analysis using all kinetic parameters that were correlated in univariate analysis with apoA-I FCR with a value of P Ͻ .10, except apoA-I PR. apoA-I FCR was independently associated with apoA-II FCR (P Ͻ .0001), VLDL 1 -TG indirect FCR (P ϭ .001), and VLDL 1 -TG PR (P ϭ .048) ( Table 5) . Together all three variables explained 64.7% of the variability in apoA-I FCR.
Liver fat, VLDL 1 production, and apoA-I catabolism Because liver fat was associated with both apoA-I FCR and VLDL 1 production (VLDL 1 -TG PR and VLDL 1 -apoB PR) and apoA-I FCR was associated with VLDL 1 production (VLDL 1 -TG PR and VLDL 1 -apoB PR), we wanted to test whether the association between liver fat and apoA-I FCR was driven by VLDL 1 production. After adjustment for VLDL1-TG PR, liver fat was not significantly correlated with apoA-I FCR.
Discussion
In a large multicenter in vivo kinetic study in abdominally obese individuals, we show that kinetics of VLDL 1 is an important independent determinant for apoA-I FCR and more precisely that apoA-I FCR is independently associated with both catabolism and production of VLDL 1 -TG. In addition, we show an association between liver fat and apoA-I FCR that is mostly mediated by the hepatic secretion of VLDL 1 -TG.
Lipoprotein kinetic studies have shown that VLDLs are metabolically heterogeneous, with accumulating evidence demonstrating that both the production and catabolism of large VLDL 1 and smaller VLDL 2 are regulated independently (10) . The separate evaluation of VLDL 1 and VLDL 2 metabolism is critical in the metabolic syndrome or type 2 diabetes in which variations in plasma TG concentrations are mainly related to differences in VLDL1, and hepatic overproduction of VLDLs is mainly due to increased hepatic secretion of VLDL 1 particles (11, 12) . To enhance our understanding of the pathways leading to VLDL 1 and VLDL 2 and of the metabolic fate of these particles, we used a multicompartmental mathematical model that allows the kinetics of TGs and apoB100 in VLDL 1 and VLDL 2 to be simultaneously assessed after a bolus injection of glycerol and leucine. Using this model, we have gained further insight into the relationship between the metabolism of TG-rich lipoproteins and the catabolism of HDL and to show that VLDL 1 kinetics modulate HDL-apoA-I turnover.
We show that apoA-I FCR is independently associated with both catabolism and production of VLDL 1 -TG, indicating that kinetics of VLDL 1 is an important independent determinant for apoA-I FCR. Our data indicate that VLDL 1 -TG indirect FCR, representing the catabolism of VLDL 1 particles mediated by lipoprotein lipase, is an important factor that is negatively associated with HDL apoA-I FCR. Consistent with these data, increase in VLDL (or VLDL 1 ) FCR induced by n-3 polyunsaturated fatty acid supplementation or by rosuvastatin have been shown to be significantly associated with reduction of HDLapoA-I catabolism (15, 20 -22) . Moreover, our data indicate that VLDL 1 PR is also an independent regulator of HDL-apoA-I catabolism. This is in line with data from a kinetic study performed in abdominally obese men that showed that the reduction of VLDL production by weight loss was accompanied by a significant decrease in HDLapoA-I catabolism (23) . Hence, our data strongly suggest that the hypercatabolism of HDL-apoA-I observed in abdominal obesity may be the consequence of dysregulated metabolism of VLDL 1 particles including both increased VLDL 1 production and reduced VLDL 1 catabolism. Increased production and reduced catabolism of VLDL 1 particles result in an expanded pool of VLDL 1 , which are large triglyceride-rich lipoproteins. This may promote CETP-mediated triglyceride enrichment of HDL particles and, as a consequence, enhance HDL catabolism (24) .
We also newly demonstrate that liver fat, assessed by proton magnetic resonance spectroscopy, is a positive and independent predictor of HDL apoA-I catabolism among morphological and biological variables. However, visceral fat was not found to be associated with HDL apoA-I FCR. Increased VLDL 1 -apoB or VLDL 1 -TG production rate has been shown to be positively correlated with liver fat (11) . In our study, we showed that the correlation between liver fat and HDL apoA-I FCR was not significant after adjustment for VLDL1-TG PR. This suggests that the association between liver fat and apoA-I FCR is mostly mediated by the hepatic production of VLDL1-TG.
When analyzing the consequent variables associated with HDL apoA-I FCR, we found that HDL-C to apoA-I ratio was negatively associated with apoA-I catabolism. Thus, overcatabolism of HDL in abdominal obesity is associated with smaller size HDL particles with reduced cholesterol content. This is in line with the negative correlation between HDL particle size and apoA-I FCR previously reported (9) . It is also consistent with increased triglyceride transfer from VLDL to HDL mediated by CETP that results in the formation of smaller triglyceriderich HDL particles that are rapidly catabolized by hepatic lipase in insulin resistance.
In addition, we newly demonstrate an independent association between apoA-I and apoA-II catabolism. In several low HDL cholesterol states, apoA-I FCR and apoA-II FCR are modified to the same extent. For example, a parallel increase in apoA-I FCR and apoA-II FCR has been reported in patients with primary HDL deficiency (25) as well as in individuals with the metabolic syndrome (12) . In addition, the link between apoA-I and apoA-II catabolism is also suggested by a study showing that apoA-I facilitates hepatic lipase-mediated hydrolysis in apoA-II containing HDL particles (26) . Collectively, our data indicate a robust, direct relationship between the catabolism of apoA-I and apoA-II, consistent with the tight structural nexus of these apoproteins in biogenesis and the disposal of HDL particles.
In the present study, we observe a very strong association between apoAI FCR and apoAI PR that has previ- ously been reported (8) . Although a direct mathematical link exists between PR and FCR because PR is calculated with FCR as a variable, we cannot exclude balancing feedback mechanisms between apoAI FCR and apoAI PR. However, this hypothesis needs further investigation.
We consider that the strong association between VLDL 1 kinetics and HDL-apoA-I catabolism has important implications. For instance, in conditions of abdominal obesity, the reduction of hepatic secretion of VLDL 1 , and/or an increase in the catabolism of VLDL 1 by weight loss and physical exercise will regulate the catabolism of HDL, resulting in a long-term increase in HDL cholesterol. In addition, an increase in HDL-apoA-I catabolism can result in dysfunctional, proatherogenic HDL particles, with an impaired capacity to effect cellular cholesterol efflux and a reduced antioxidative and anti-inflammatory properties (27) . Hence, lifestyle interventions, such as weight regulation and aerobic exercise, may correct HDL overcatabolism and dysfunctionality by decreasing the hepatic secretion of the VLDL 1 subspecies.
Our investigation has the limitations of a cross-sectional design. We studied more men than women and might have missed gender differences in the relationship between the kinetics of VLDL subspecies and HDL apoA-I. We did not study the kinetics of HDL subspecies or the turnover of LpA-I and LpA-I:A-II particles. This requires further investigation but would expect that an expanded VLDL 1 pool size would result in accelerate catabolism in all HDL particles, with a preferential reduction in smaller size particles (12) .
In conclusion, we demonstrated that VLDL 1 is an important independent determinant for apoA-I FCR and more precisely that apoA-I FCR is independently associated with both catabolism and production of VLDL 1 -TG. In addition, we show an association between liver fat and apoA-I FCR that is mostly mediated by VLDL 1 -TG production. These data indicate that, in abdominal obesity, dysfunctional VLDL 1 metabolism is an important modulator of HDL apoA-I catabolism.
